Developmental and epileptic encephalopathy, 4
MONDO:0012812Early infantile epileptic encephalopathy 4 (EIEE4) is a form of early infantile epileptic encephalopathy, which refers to a group of neurological conditions characterized by severe seizures beginning in infancy. EIEE4, specifically, is often associated with partial complex or tonic-clonic seizures, although other seizure types have been reported. Other signs and symptoms mayinclude intellectual disability, reduced muscle tone (hypotonia), hypsarrhythmia (an irregular pattern seen on EEG), dyskinesia (involuntary movement of the body), and spastic di- or quadriplegia. EIEE4 is caused by changes (mutations) in the STXBP1 gene and is inherited in an autosomal dominant manner. Treatment is based on the signs and symptoms present in each person. For example, certain medications are often prescribed to help control seizures, although they are not always effective in all people with the condition.
Also known as: DEE4, EIEE4, STXBP1 early infantile epileptic encephalopathy, STXBP1-related encephalopathy, developmental and epileptic encephalopathy 4, developmental and epileptic encephalopathy, 4, early infantile epileptic encephalopathy 4, early infantile epileptic encephalopathy caused by mutation in STXBP1
42 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Gene therapy trial for rare childhood epilepsy halted after just one patient
Disease control TerminatedThis trial tested a single dose of CAP-002 gene therapy in children aged 18 months to 8 years with STXBP1 encephalopathy, a rare genetic brain disorder causing seizures and developmental delays. The study aimed to check safety and whether it could reduce seizures and improve skil…
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for Tough-to-Treat seizures in kids
Disease control TerminatedThis study looked at the long-term safety of soticlestat, an experimental drug, in children and adults with severe forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. Participants took soticlestat twice a day along with their usual seizure medicines. The study was…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC